Literature DB >> 3025888

Gastroenteritis caused by human rotaviruses (serotype three) in a suckling mouse model.

L M Bell, H F Clark, E A O'Brien, M J Kornstein, S A Plotkin, P A Offit.   

Abstract

The pathogenic potential of human rotaviruses of serotypes 1 through 4 was evaluated in suckling mice. Oral inoculation of three different human rotaviruses of serotype 3 into 5-6 day old CD-1 mice caused disease characterized by diarrhea and dehydration. The mean 50% diarrhea inducing dose (DD50) was 5 X 10(5) pfu. Histopathological examination of small intestines revealed villus epithelial cell vacuolization localized to the distal one-third of the villus. Only Serotype 3 rotaviruses exhibited a rapid phase of viral growth in the intestine between 7 and 12 hours post-inoculation. Larger inocula of rotavirus serotypes 1, 2, and 4 did not cause disease or typical histopathologic changes. However, immunoperoxidase staining for rotavirus antigen was positive in all serotypes tested indicating that infection can occur without apparent disease and is not serotype specific. This convenient in-vivo model can be used to evaluate attenuation of human origin vaccine candidates of serotype 3.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3025888     DOI: 10.3181/00379727-184-rc2

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  13 in total

1.  Rotavirus-specific cytotoxic T lymphocytes cross-react with target cells infected with different rotavirus serotypes.

Authors:  P A Offit; K I Dudzik
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

2.  Characterization of a novel G3P[3] rotavirus isolated from a lesser horseshoe bat: a distant relative of feline/canine rotaviruses.

Authors:  Biao He; Fanli Yang; Weihong Yang; Yuzhen Zhang; Yun Feng; Jihua Zhou; Jinxin Xie; Ye Feng; Xiaolei Bao; Huancheng Guo; Yingying Li; Lele Xia; Nan Li; Jelle Matthijnssens; Hailin Zhang; Changchun Tu
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

3.  Rotavirus isolate WI61 representing a presumptive new human serotype.

Authors:  H F Clark; Y Hoshino; L M Bell; J Groff; G Hess; P Bachman; P A Offit
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

4.  Treatment of rotaviral gastroenteritis with Qiwei Baizhu powder.

Authors:  S T He; F Z He; C R Wu; S X Li; W X Liu; Y F Yang; S S Jiang; G He
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

5.  Extramucosal spread and development of hepatitis in immunodeficient and normal mice infected with rhesus rotavirus.

Authors:  I Uhnoo; M Riepenhoff-Talty; T Dharakul; P Chegas; J E Fisher; H B Greenberg; P L Ogra
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

6.  Subgroup and serotype distributions of human, bovine, and porcine rotavirus in Thailand.

Authors:  Y Pongsuwanne; K Taniguchi; M Choonthanom; M Chiwakul; T Susansook; S Saguanwongse; C Jayavasu; S Urasawa
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

7.  Development of a human rotavirus induced diarrhea model in Chinese mini-pigs.

Authors:  Jin-Tao Li; Jing Wei; Hong-Xia Guo; Jiang-Bo Han; Nan Ye; Hai-Yang He; Tian-Tian Yu; Yu-Zhang Wu
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

8.  Murine rotavirus genes encoding outer capsid proteins VP4 and VP7 are not major determinants of host range restriction and virulence.

Authors:  R L Broome; P T Vo; R L Ward; H F Clark; H B Greenberg
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

9.  Rotavirus-specific intestinal immune response in mice assessed by enzyme-linked immunospot assay and intestinal fragment culture.

Authors:  C A Khoury; K A Brown; J E Kim; P A Offit
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

10.  Development of a heterologous model in germfree suckling rats for studies of rotavirus diarrhea.

Authors:  C Guerin-Danan; J C Meslin; F Lambre; A Charpilienne; M Serezat; C Bouley; J Cohen; C Andrieux
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.